Investigator Racial Diversity and Clinical Trial Participation
How to cite
Alsan, Marcella; Leister, Lukas; Campbell, Romaine; Ojo, Ayotomiwa. 2023. "Investigator Racial Diversity and Clinical Trial Participation." AEA RCT Registry. AEARCTR-0011926. https://doi.org/10.1257/rct.11926-1.1
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Participation of Black patients in clinical trials remains low relative to population and disease-burden benchmarks. We investigate whether increased racial diversity of trial principal investigators could increase enrollment of Black patients. To do so, we conducted a survey experiment in which respondents were shown a photo of a current NIH investigator in which race (Black/White) was cross-randomized as was gender (male/female) to provide a relevant benchmark. Black respondents reported 10.5 percent higher interest in participating in a clinical study led by a race concordant investigator. Gender concordance had no effect. Multivariate regression analyses point to perceived trustworthiness as the most important factor in explaining the pattern of results. Our findings suggest that increasing the racial diversity of clinical trial investigators is a potentially effective method for encouraging enrollment of Black participants in medical research.
*Please see ClinicalTrials.gov NCT04938895 for more information and pre-registration.
Intervention
We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photograph of a real NIH investigator. We experimentally vary treatment along two dimensions: whether the sender is Black or white and whether the sender is male or female.
Experimental design
We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photograph of a real NIH investigator. We experimentally vary treatment along two dimensions: whether the sender is Black or white and whether the sender is male or female.
Our primary aim is to assess whether the subject's stated willingness to participate in a clinical trial led by the investigator. Our secondary aim is to assess whether the subject is a more objective measure of interest in signing up for information on other clinical trials. To assess mechanisms, we will ask the respondent to rate the subject's perceived trustworthiness and quality of the investigator. In addition, we will also assess the subject's perceived attractiveness and age of the investigator as well as the subject's risk aversion, altruism, time preference, and general trust.
Design details
Cited by
No citation data available for this registration yet.